Literature DB >> 17111050

Why adefovir is not yet available in Canada.

Morris Sherman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17111050      PMCID： PMC2660823          DOI： 10.1155/2006/826093

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  19 in total

1.  Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.

Authors:  T Santantonio; M Mazzola; T Iacovazzi; A Miglietta; A Guastadisegni; G Pastore
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

2.  Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

Authors:  E K Manesis; S J Hadziyannis
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Authors:  N W Leung; C L Lai; T T Chang; R Guan; C M Lee; K Y Ng; S G Lim; P C Wu; J C Dent; S Edmundson; L D Condreay; R N Chien
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

Authors:  N C Tassopoulos; R Volpes; G Pastore; J Heathcote; M Buti; R D Goldin; S Hawley; J Barber; L Condreay; D F Gray
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

5.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Authors:  S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

6.  Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; G V Papatheodoridis; E Dimou; A Laras; C Papaioannou
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

7.  HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.

Authors:  Vito Di Marco; Rosa Di Stefano; Donatella Ferraro; Piero Luigi Almasio; Celestino Bonura; Maria Giglio; Pietro Parisi; Maria Cappello; Giuseppe Alaimo; Antonio Craxì
Journal:  Antivir Ther       Date:  2005

8.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Barbara Coco; Gioacchino Leandro; Piero Colombatto; Juliana Monti Gorin; Ferruccio Bonino
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

9.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

10.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.